ABT Abbott Laboratories

Q3 2025 10-Q

Filed: Oct 29, 2025Period ending Sep 30, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Abbott Laboratories (ABT) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 29, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Revenue $11.37B Q3 2025, up 6.9% YoY vs $10.64B Q3 2024, excluding FX impact increase 5.5%
• Gross margin 51.7% Q3 2025 vs 51.4% Q3 2024, Nine months margin 52.4% vs 51.0% YoY

+3 more insights

Risk Factors

• Section 'risk_factors' was empty or not found.

Quarterly Financial Summary
XBRL

Revenue

$11.4B

▲ +6.9% YoY▲ +2.0% QoQ

Net Income

$1.6B

▼ -0.1% YoY▼ -7.6% QoQ

Operating Margin

18.1%

▲ +61bp YoY▼ -32bp QoQ

Net Margin

14.5%

▼ -102bp YoY▼ -151bp QoQ

ROE

3.2%

Total Assets

$84.2B

EPS (Diluted)

$0.93

▼ -1.1% YoY▼ -7.9% QoQ

Operating Cash Flow

$2.8B

▲ +3.0% YoY▲ +36.2% QoQ

Source: XBRL data from Abbott Laboratories Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Abbott Laboratories

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.